| Pfizer Inc.announced 5 May 2026 |
Start approximately 20 key pivotal studies in its late-stage R&D pipeline |
Open31 Dec 2026 |
| Pfizer Inc.announced 3 Feb 2026 |
Start approximately 20 key pivotal trials during 2026 |
Open31 Dec 2026 |
| Pfizer Inc.announced 13 Oct 2023 |
Provide NDA-labeled commercial supply of Paxlovid to all channels |
Met31 Dec 2023 |
| Pfizer Inc.announced 13 Oct 2023 |
Accept return of EUA-labeled Paxlovid treatment courses |
Met31 Dec 2023 |
| Pfizer Inc.announced 13 Oct 2023 |
Provide Paxlovid free of charge to federally insured patients through a patient assistance program |
No record found31 Dec 2024 |
| Pfizer Inc.announced 13 Oct 2023 |
Supply treatment courses for the U.S. Strategic National Stockpile |
Open31 Dec 2028 |
| Pfizer Inc.announced 13 Oct 2023 |
Offer a copay program for privately insured patients |
Open31 Dec 2028 |
| Pfizer Inc.announced 13 Oct 2023 |
Provide Paxlovid free of charge to uninsured and underinsured patients through a patient assistance program |
Open31 Dec 2028 |
| Pfizer Inc.announced 1 Aug 2023 |
Make Ngenla available for prescribing in the U.S |
No record found31 Aug 2023 |
| Pfizer Inc.announced 1 Aug 2023 |
Transition Paxlovid and Comirnaty to traditional commercial markets in the U.S |
Met31 Dec 2023 |
| Pfizer Inc.announced 13 Mar 2023 |
Close the acquisition of Seagen |
Met31 Mar 2024 |
| Pfizer Inc.announced 1 Nov 2022 |
Deliver Comirnaty doses previously scheduled for June through August 2022 |
No record found31 Dec 2022 |
| Pfizer Inc.announced 1 Nov 2022 |
Launch up to 19 new products or indications |
No record found1 May 2024 |
| Pfizer Inc.announced 10 May 2022 |
Close the acquisition of Biohaven Pharmaceutical Holding Company Ltd |
Met31 Mar 2023 |
| Pfizer Inc.announced 30 Oct 2020 |
Close the combination of Mylan and Pfizer's Upjohn business |
Met16 Nov 2020 |
| Pfizer Inc.announced 28 Jan 2020 |
Report proof-of-concept readouts for PF-06939926 |
Met30 Jun 2020 |
| Pfizer Inc.announced 28 Jan 2020 |
Report top-line results for the JADE Compare study |
No record found30 Jun 2020 |
| Pfizer Inc.announced 28 Jan 2020 |
Report top-line results for three Phase 3 trials of PF-06482077 |
Not met30 Jun 2020 |
| Pfizer Inc.announced 28 Jan 2020 |
Report top-line results for Xeljanz in ankylosing spondylitis |
No record found30 Jun 2020 |
| Pfizer Inc.announced 28 Jan 2020 |
Report top-line results for the Phase 3 PENELOPE-B study |
No record found31 Dec 2020 |
| Pfizer Inc.announced 28 Jan 2020 |
Report proof-of-concept readouts for PF-06651600 |
Late31 Dec 2020 |
| Pfizer Inc.announced 28 Jan 2020 |
Complete the Phase 3 PALLAS study |
No record found31 Mar 2021 |
| Pfizer Inc.announced 19 Dec 2019 |
Complete the combination of Mylan N.V. and Upjohn Inc |
Late30 Jun 2020 |
| Pfizer Inc.announced 29 Jul 2019 |
Form the Consumer Healthcare joint venture with GlaxoSmithKline plc |
Met1 Aug 2019 |
| Pfizer Inc.announced 29 Jul 2019 |
Close the transaction to combine Mylan with Upjohn |
Not met30 Jun 2020 |
| Pfizer Inc.announced 17 Jun 2019 |
Close the acquisition of Array BioPharma |
Met31 Dec 2019 |
| Pfizer Inc.announced 30 Apr 2019 |
Deliver Phase 3 clinical trial readouts for PF-04965842 and rivipansel |
Not met31 Dec 2019 |
| Pfizer Inc.announced 29 Jan 2019 |
Report pivotal results for rivipansel in vaso-occlusive crisis from sickle cell disease |
No record found31 Dec 2019 |